Streptococcus Salivarius Evol12® in Improving Quality of Life in Locally Advanced Head and Neck Cancer Treated With Radio(Chemo)Therapy: SMILE (SMILE)
Streptococcus Salivarius Evol12® in Improving Quality of Life In Locally Advanced Head and Neck Cancer Treated With radiochEmotherapy: SMILE, a Monocentric National Randomized Double Blind Interventional Study
The clinical study will involve the use of a dietary supplement based on the oral probiotic strain Streptococcus salivarius Evol12® in patients with head and neck cancer undergoing radiochemotherapy, with the aim of improving their quality of life. The hypothesis is that, as already outlined in scientific literature, modifying the oral microbiota through the use of the commensal S. salivarius, increasing its concentration and reducing the main pathogens in the oral cavity, may protect these patients and reduce the impact on their quality of life . A discovery of this kind would allow patients with head and neck cancer to be treated not only with standard therapy but also with treatments designed to modify the oral microbiota, which is not currently taken into consideration, in order to improve these patients' quality of life and compliance with treatment. Compared to the S. salivarius K12 strain, the S. salivarius eK12 (Evol12®) strain has a genome that is entirely similar to K12, but with a hypothetically greater antibacterial activity due to the presence of two specific genetic differences which allow for increased release of a bacteriocin: the salivabactin. Streptococcus salivarius eK12 (Evol12®) has undergone mutagenesis, acute toxicity, and subchronic toxicity studies in animals, conducted according to OECD guidelines by a GLPcertified laboratory, confirming its safety of use and absence of toxicity (In vitro and In vivo safety evaluation of Streptococcus salivarius eK12, a genetically modified dietary probiotic derived from the oral probiotic S. salivarius K12). In addition, a randomized, double-blind, placebo-controlled clinical trial conducted in healthy adults has been published, demonstrating its complete safety of use even at high dosages.
調査の概要
状態
状態
条件
条件
介入・治療
介入・治療
研究の種類
研究の種類
入学 (推定)
入学
段階
段階
- 適用できない
連絡先と場所
研究連絡先
研究連絡先
- 名前:Aurora Mirabile Medical oncologist
- 電話番号:+39 02 2643 3526
- メール:mirabile.aurora@hsr.it
参加基準
適格基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Participants are willing and able to give informed consent for participation in the study.
- Aged >=18 years
- Patients diagnosed with non-metastatic head and neck malignant tumors, with an Eastern Cooperative Oncology Group performance status of ≤2, planning to receive definitive RT or postoperative adjuvant RT concomitant to cisplatin.
- Patient affected by squamocellular carcinoma of oral cavity, larynx, hypopharynx, oropharynx and undifferentiated or squamocellular carcinoma of nasopharynx.
- Patients eligible for to receive definitive RT or postoperative adjuvant RT concomitant to cisplatin.
Exclusion Criteria:
- Patients with a history of allergy to probiotics or severe allergic constitution
- Use of antibiotics/antifungal drugs within 1 month or antimicrobial mouthwash within 1 week before the study
- Poor oral hygiene and/or severe periodontal diseases (CTCAE 5.0 Grading >/=2)
- Any previous RT to the head and neck region
- Those deemed unsuitable for the study by the investigators (concomitant with any other severe diseases)
- Allergies: history of known allergies to probiotics or to product excipients.
- Recent antimicrobial therapies: use of systemic antibiotics or antifungals within 1 month, or antimicrobial mouthwashes within 1 week.
- Oral cavity conditions: severely compromised oral hygiene or severe periodontal disease.
- Previous radiotherapy: any prior radiotherapy (RT) to the head and neck region.
- Severe comorbidities: severe concomitant diseases that make the patient unsuitable according to clinical judgment.
- Pregnancy and breastfeeding
- Contraindication related to probiotic composition
- Primary sites different from the ones described in inclusion criteria
- Patient unfit to cisplatin
- Immunocompromised Patients
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:支持療法
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:ダブル
アーム数
武器と介入
参加者グループ / アーム参加者グループ / アーム |
介入・治療介入・治療 |
|---|---|
|
プラセボコンパレーター:placebo group
The placebo lozenges will be identical in appearance, taste, and composition, but will contain only excipients (sugar and starch), without any active bacteria. |
Participants will be instructed to slowly dissolve one lozenge in the mouth three times daily (morning, afternoon, and evening) throughout the entire radiotherapy (RT) period. Patients will also be advised to avoid eating, drinking, or performing oral hygiene procedures for at least one hour after administration |
|
実験的:group treated with probiotic: Streptococcus salivarius Evol12®
The investigational product (Bactoblis® Evol, containing the probiotic strain Streptococcus salivarius Evol12®) will be provided in the form of oral lozenges, each containing ≥ 1 × 10⁹ colony-forming units (CFU) of viable S. salivarius Evol12® cells as the active ingredient. Participants will be instructed to slowly dissolve one lozenge in the mouth three times daily (morning, afternoon, and evening) throughout the entire radiotherapy (RT) period. |
Participants will be instructed to slowly dissolve one lozenge in the mouth three times daily (morning, afternoon, and evening) throughout the entire radiotherapy (RT) period. Patients will also be advised to avoid eating, drinking, or performing oral hygiene procedures for at least one hour after administration, in order to ensure optimal mucosal contact and promote probiotic colonization. |
この研究は何を測定していますか?
主要な結果の測定
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
EORTC QLQ-H&N35 score
時間枠:It will be assessed before treatment, 3 weeks, 8 weeks and subsequently for up to 8 weeks.
|
Change in quality of life assessed using the EORTC QLQ-H&N35 scale before treatment, 3 weeks, at the end of treatment (8 weeks) and thereafter for up to 8 weeks. |
It will be assessed before treatment, 3 weeks, 8 weeks and subsequently for up to 8 weeks.
|
二次結果の測定
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
days
時間枠:It will be assessed before treatment, 3 weeks, 8 weeks and subsequently for up to 8 weeks.
|
Time to onset (days) of WHO grade ≥2 and ≥3. |
It will be assessed before treatment, 3 weeks, 8 weeks and subsequently for up to 8 weeks.
|
|
days
時間枠:It will be assessed before treatment, 3 weeks, 8 weeks and subsequently for up to 8 weeks.
|
Duration (days) of WHO grade ≥2 and ≥3. |
It will be assessed before treatment, 3 weeks, 8 weeks and subsequently for up to 8 weeks.
|
|
Percentage
時間枠:It will be assessed before treatment, 3 weeks, 8 weeks and subsequently for up to 8 weeks.
|
Rate of RT/chemotherapy interruptions, dose reduction or delay due to toxicity. |
It will be assessed before treatment, 3 weeks, 8 weeks and subsequently for up to 8 weeks.
|
|
Numeric Rating Scale (NRS)
時間枠:It will be assessed before treatment, 3 weeks, 8 weeks and subsequently for up to 8 weeks.
|
Change in Pain Scores Over Time, assessed using the Numeric Rating Scale (NRS; 0-10), where 0 indicates no pain and 10 indicates the worst pain imaginable. Higher scores indicate greater pain intensity and a worse outcome. |
It will be assessed before treatment, 3 weeks, 8 weeks and subsequently for up to 8 weeks.
|
|
Percentage
時間枠:It will be assessed before treatment, 3 weeks, 8 weeks and subsequently for up to 8 weeks.
|
Percentage of patients requiring enteral or parenteral nutritional support according to the percentage of weight loss (≥5% o ≥10%). |
It will be assessed before treatment, 3 weeks, 8 weeks and subsequently for up to 8 weeks.
|
|
days
時間枠:It will be assessed before treatment, 3 weeks, 8 weeks and subsequently for up to 8 weeks.
|
duration of RT/chemotherapy interruptions, dose reduction or delay due to toxicity. |
It will be assessed before treatment, 3 weeks, 8 weeks and subsequently for up to 8 weeks.
|
協力者と研究者
研究記録日
主要日程の研究
研究開始 (推定)
研究開始
一次修了 (推定)
一次修了
研究の完了 (推定)
研究の完了
試験登録日
最初に提出
最初に提出
QC基準を満たした最初の提出物
QC基準を満たした最初の提出物
最初の投稿 (実際)
最初の投稿
学習記録の更新
投稿された最後の更新 (実際)
投稿された最後の更新
QC基準を満たした最後の更新が送信されました
QC基準を満たした最後の更新が送信されました
最終確認日
最終確認日
詳しくは
本研究に関する用語
キーワード
その他の研究ID番号
その他の研究ID番号
- SMILE
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。